First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...
The tibremciclib trial demonstrated a significant PFS benefit and high objective response rates in a single-country cohort without prior CDK4/6 inhibitor exposure. Overall survival (OS) data remain ...
Please provide your email address to receive an email when new articles are posted on . CDK4/6 inhibitors in the earlier setting did not lead to statistically significant PFS or OS improvement. The ...
Tuojie Biotech (Shanghai) Co. Ltd. has prepared oxygen-containing fused tricyclic derivatives acting as CDK2/cyclin E1 and/or CDK4/cyclin D1 inhibitors. As such, they are reported to be potentially ...
Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, ...
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
An Allorion Therapeutics (Guangzhou) Co. Ltd. patent discloses aminoheteroaryl CDK4/cyclin D1 inhibitors reported to be useful for the treatment of cancer.
Avenzo Therapeutics Advances Combination of AVZO-023 (CDK4i) with AVZO-021 (CDK2i) in Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer ...
Cyclin D1 is overexpressed in certain solid tumors and hematologic malignancies. In these cancers, the cyclin D1/CDK4 complex drives cell proliferation by binding to the tumor suppressor ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results